SIGNIFOR LAR pasireotide 60 mg (as embonate) modified release powder for injection vial and 2 mL diluent in prefilled syringe composite pack Australia - English - Department of Health (Therapeutic Goods Administration)

signifor lar pasireotide 60 mg (as embonate) modified release powder for injection vial and 2 ml diluent in prefilled syringe composite pack

recordati rare diseases australia pty ltd - pasireotide embonate, quantity: 82.26 mg (equivalent: pasireotide, qty 60 mg) - injection, modified release - excipient ingredients: polyglactin glucose; polyglactin - signifor lar is indicated for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative or who are inadequately controlled on treatment with other somatostatin analogues.

SIGNIFOR LAR pasireotide 40 mg (as embonate) modified release powder for injection vial and 2 mL diluent in prefilled syringe composite pack Australia - English - Department of Health (Therapeutic Goods Administration)

signifor lar pasireotide 40 mg (as embonate) modified release powder for injection vial and 2 ml diluent in prefilled syringe composite pack

recordati rare diseases australia pty ltd - pasireotide embonate, quantity: 54.84 mg (equivalent: pasireotide, qty 40 mg) - injection, modified release - excipient ingredients: polyglactin glucose; polyglactin - signifor lar is indicated for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative or who are inadequately controlled on treatment with other somatostatin analogues.

SIGNIFOR LAR pasireotide 20 mg (as embonate) modified release powder for injection vial and 2 mL diluent in prefilled syringe composite pack Australia - English - Department of Health (Therapeutic Goods Administration)

signifor lar pasireotide 20 mg (as embonate) modified release powder for injection vial and 2 ml diluent in prefilled syringe composite pack

recordati rare diseases australia pty ltd - pasireotide embonate, quantity: 27.42 mg (equivalent: pasireotide, qty 20 mg) - injection, modified release - excipient ingredients: polyglactin glucose; polyglactin - signifor lar is indicated for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative or who are inadequately controlled on treatment with other somatostatin analogues.

SIGNIFOR pasireotide 900 microgram/1 mL (as diaspartate) solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

signifor pasireotide 900 microgram/1 ml (as diaspartate) solution for injection ampoule

recordati rare diseases australia pty ltd - pasireotide diaspartate, quantity: 1128.6 microgram (equivalent: pasireotide, qty 900 microgram) - injection, solution - excipient ingredients: mannitol; water for injections; sodium hydroxide; tartaric acid - the treatment of adult patients with cushing?s disease for whom surgery is not an option or for whom surgery has failed.

SIGNIFOR pasireotide 300 microgram/1 mL (as diaspartate) solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

signifor pasireotide 300 microgram/1 ml (as diaspartate) solution for injection ampoule

recordati rare diseases australia pty ltd - pasireotide diaspartate, quantity: 376.2 microgram (equivalent: pasireotide, qty microgram) - injection, solution - excipient ingredients: water for injections; mannitol; tartaric acid; sodium hydroxide - the treatment of adult patients with cushing?s disease for whom surgery is not an option or for whom surgery has failed.

SIGNIFOR pasireotide 600 microgram/1 mL (as diaspartate) solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

signifor pasireotide 600 microgram/1 ml (as diaspartate) solution for injection ampoule

recordati rare diseases australia pty ltd - pasireotide diaspartate, quantity: 752.4 microgram (equivalent: pasireotide, qty 600 microgram) - injection, solution - excipient ingredients: water for injections; sodium hydroxide; tartaric acid; mannitol - the treatment of adult patients with cushing?s disease for whom surgery is not an option or for whom surgery has failed.

CYSTADANE betaine 1g/g oral powder bottle Australia - English - Department of Health (Therapeutic Goods Administration)

cystadane betaine 1g/g oral powder bottle

recordati rare diseases australia pty ltd - betaine, quantity: 1 g/g - powder, oral - excipient ingredients: - as an adjunct in the treatment of homocystinuria.

Betaloc 1 mg/ml solution for injection Ireland - English - HPRA (Health Products Regulatory Authority)

betaloc 1 mg/ml solution for injection

recordati ireland limited - metoprolol tartrate - solution for injection - 1 milligram(s)/millilitre - beta blocking agents, selective; metoprolol

Depo-Eligard 22.5 mg inj. sol. (pwdr. + solv.) s.c. pre-filled syr. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

depo-eligard 22.5 mg inj. sol. (pwdr. + solv.) s.c. pre-filled syr.

recordati industria chimica e farmaceutica s.p.a. - leuprorelin acetate 22,5 mg - eq. leuprorelin 20,87 mg - powder and solvent for solution for injection - 22,5 mg - leuprorelin acetate 22.5 mg - leuprorelin

Depo-Eligard 7.5 mg inj. sol. (pwdr. + solv.) s.c. pre-filled syr. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

depo-eligard 7.5 mg inj. sol. (pwdr. + solv.) s.c. pre-filled syr.

recordati industria chimica e farmaceutica s.p.a. - leuprorelin acetate 7,5 mg - eq. leuprorelin 6,96 mg - powder and solvent for solution for injection - 7,5 mg - leuprorelin acetate 7.5 mg - leuprorelin